Autoimmune Cholangitis: Is It an Antimitochondrial Antibody Negative Primary Biliary Cirrhosis? by Omagari Katsuhisa
Acta Med. Nagasaki 44 : 11-14
- Review Article -
Autoimmune Cholangitis: Is It an Antimitochondrial Antibody 
Negative Primary Biliary Cirrhosis?
Katsuhisa OMAGARI
Second Department of Internal Medicine, Nagasaki University School of Medicine, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan
 Autoimmune cholangitis/cholangiopathy (AIC) is a re-
cently described disease characterized by chronic 
cholangitis resembling primary biliary cirrhosis (PBC) with 
a high frequency of antinuclear antibodies (ANA) and with 
sero-negativity for antimitochondrial antibodies (AMA). 
Whether AIC is a disease entity distinct from PBC and 
autoimmune hepatitis (AIH) or whether it is an AMA-
negative variant of PBC or a cholangiopathic variant of 
AIH have so far been controversial. We recently examined 
the specificities of AMA and ANA in Japanese patients 
with AIC, PBC and AIH by immunofluorescence, 
immunoblotting and enzyme inhibition assays using various 
mitochondrial and nuclear autoantigens including 2-oxo-
acid dehydrogenase complex, Sp100, gp210, and p62, and 
found that AIC and PBC had similar patterns of 
immunoreactivity. However, this duo is of interest because, 
usually, among sets of autoimmune syndromes, differences 
in serological targetting are matched by differences in 
clinical presentation: AIC and PBC seem to be an exception 
to this rule. While it is true that a single etiological agent 
can produce a wide range of disease expression, it is possi-
ble that seemingly similar clinicopathological features can 
be induced by pathogenetic mechanisms caused by a diver-
sity of etiological agents.
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Introduction
Autoimmune hepatitis (AIH), primary biliary cirrho-
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sis (PBC), and primary sclerosing cholangitis (PSC ) 
are regarded as autoimmune liver diseases. AIH is a 
chronic necroinflammatory liver disease of unknown 
etiology and characterized by immunological features, 
including hypergamma-globulinemia and circulating 
autoantibodies such as antinuclear antibodies (ANA).') 
On the other hand, PBC is a chronic, progressive 
cholestatic liver disease of unknown cause that usually 
affects middle-aged woman.') Antimitochondrial anti-
bodies (AMA) are found in 95% of patients with PBC, 
and they have a specificity of more than 98% for this 
disease.') The distinction between AIH and PBC is in 
general based on above characteristic clinical, 
histologic, and immunologic features. However, there 
have been several reports on liver diseases marked by 
coexisting features of PBC and AIH4'S) 
 In this context, considerable interest has been gener-
ated in a novel chronic liver disease recognized as 
autoimmune cholangitis/cholangiopathy (AIC) since 
the first report of this disease in 1987.6) In that report 
and subsequent studies,'-'') the clinical and histopa-
thological features of AIC were characterized as an in-
flammatory intrahepatic cholangitis with sero-
negativity for AMA and a high frequency of ANA. 
The disease resembles PBC in many respects including 
survival experience,") although early reports cited a 
more favorable response to treatment with 
corticosteroids6-8> Thus, it is unclear at present whether 
AIC is distict from PBC7 9' or whether AIC is consid-
ered as an AMA sero-negative variant of PBC,10-15) or a 
cholangiopathic variant of AIH 8)'6) Detailed serological 
specificities of AMA and ANA, tested using recently 
developed assays, have not been described hitherto in 
AIC although the study of a single case of AIC led us 
to surmise that the disease resembled PBC since the 
serum reacted by immunoblotting with an E2 subunit 
(50-52 kDa) of one of the lower molecular weight 2-
oxo-acid dehydrogenase complexes (2-OADC), anti-
genic components specific for PBC serum, and
exhibited by immunofluorescence the multiple nuclear 
dots and nuclear membrane patterns indicating the 
presence of anti-Sp 100 and anti-gp210.13'
Definition of "autoimmune cholangitis/ 
cholangiopathy"
  The term "immunocholangitis" was introduced first 
by BrUnner and Klinges' in 1987. The authors de-
scribed a condition seen in three women who had 
clinical, histological and biochemical liver abnormali-
ties fulfilling the criteria of PBC but were sero-positive 
for ANA and sero-negative for AMA. The three pa-
tients responded well to immunosuppressive treatment 
with azathioprine and prednisolone. Carrougher et al." 
also reported a relatively young woman with clinical, 
pathologic, and serologic features of both AIH and 
PBC. The positive ANA, negative AMA, and favorable 
response to corticosteroid therapy were similar to the 
cases reported by Brunner and Klinge.s' Ben-Ari et al." 
described four such patients who were also sero-
positive for smooth muscle antibody (SMA). 
  Subsequent to the above three reports, attention has 
focused on a subgroup of patients with clinically and 
histologically diagnosed PBC who are sero-negative for 
the classical immunofluorescence pattern of AMA but 
sero-positive for ANA. The subgroup is termed 
"immunocholangitis"
,6" "autoimmune cholangitis°,9'2.14)1" 
"autoimmune cholangiopathy" ,8"6'18' "primary autoimmune 
cholangitis",10' or "immune cholangiopathy".19' Ben-Ari 
et al.') suggested that AIC probably represented a sub-
group of type 1 AIH with predominant bile duct dam-
age because the patients responded well to 
prednisolone therapy, in contrast to those with classi-
cal PBC. However, some other reports indicated that 
AIC can be considered to be the same as AMA-
negative PBC since an only consistently distinguishing 
feature between the two disease entities was the 
autoantibody (AMA and ANA) profile as both had 
otherwise virtually identical clinical and histopathologic 
features. 12'20' Moreover, Sherlock indicated only a par-
tial response to prednisolone therapy in their subse-
quent study;") inflammation was reduced but serum 
gamma-glutamyl transpeptidase level remained at the 
high levels and bile duct lesions persisted. 
Furthermore, Colombato et al."' reported a patient 
with AIC in whom this entity was the result of con-
secutive typical PBC followed by typical steroid-
dependent AIH. Thus, "sero-conversion" from AMA 
positivity to negativity by immunofluorescence or 
immunoblotting, or vice versa ,21) is a rare but 
recognised clinical situation in PBC,22' and the clinical
entity of AIC is so far unestablished (Table 1). AIC is 
not very rare since the frequency of this disease was 
reported in one study to be 11% among 225 patients 
with various autoimmune liver diseases including PBC, 
AIH and primary sclerosing cholangitis,23' and 20% 
among another group of 200 patients who had mor-
phologically consistent features of PBC.12'
Immunologic or serological markers in AIC
Table 1. Clinical features of various autoimmune 
liver diseases
 Criterion AIH AIC PBC PSC 
Target Hepatocyte Septal and intra- Septal and intra- Intra- and extra-
                          hepatic bile duct hepatic bile duct hepatic bile duct
Sex Female Female Male 
               predominance predominance predominance 
Biochemistry AST, ALT ALP, y -GTP ALP, y -GTP ALP, y -GTP 
Autoantibody ANA ANA AMA p-ANCA ? 
Immunoglobulin IgG IgG, IgM IgM 
Histopathology CAH CNSDC CNSDC Pericholangitis 
Treatment CS CS ? UDCA UDCA ?
AIH: autoimmune hepatitis, AIC: autoimmune cholangitis, PBC: primary biliary cir-
rhosis, PSC: primary sclerosing cholangitis, AST: aspartate aminotransferase, ALT: 
alanine aminotransferase, ALP: alkaline phosphatase, y -GTP: gamma-glutamyl 
transpeptidase, ANA: antinuclear antibody, AMA: antimitochondrial antibody, p-
ANCA: perinuclear-anti-neutrophil cytoplasmic antibody, CAH: chronic active hepa-
titis, CNSDC: chronic non-suppurative destructive cholangitis, CS: corticosteroid, 
UDCA: ursodeoxycholic acid
 Hitherto, no specific immunologic or serological pat-
terns of reactivity in AIC have been described, except 
the presence of an antibody to human carbonic 
anhydrase II (CA-II), one of a family of zink metal en-
zymes, reported by Gordon et al.."' However, Muratori 
et al."' reported that the antibody to CA-II seemed to 
be commonly found in a variety of pathological and 
normal conditions and was therefore unlikely to be a 
serological marker specific to AIC. On the other hand, 
Michieletti et al." reported that 3 of 20 patients diag-
nosed as PBC who were AMA-negative and ANA-
positive by immunofluorescence showed the positive 
results of antibodies to 2-OADC enzymes by immunoblotting 
and ELISA. Of these 3 sera, 2 reacted with pyruvate 
dehydrogenase complex (PDC), which has been char-
acterized as the immunodominant autoantigen in PBC, 
and 1 with branched-chain oxo-acid dehydrogenase 
complex (BCOADC) by immunoblotting. Thus, if AIC 
is, in fact, a part of the spectrum of PBC, detailed 
studies on the profile of immunoreactivities with 2-
OADC enzymes can be informative. We examined the 
specificities of AMA and ANA in 21 Japanese patients 
with AIC, 37 with classical PBC and 16 with AIH by 
immunofluorescence, immunoblotting and enzyme inhi-
bition assays using various mitochondrial and nuclear
autoantigens including 2-OADC, Sp100, gp210, and 
p62.2A' By immunoblotting, in which the sensitivity, 
specificity, positive predictive value, negative predic-
tive value, and accuracy in our assay condition were 
99%, 86%, 89%, 99%, and 93%, respectively,25' and 
notwithstanding the negative result for AMA by 
immunofluorescence, 5 (24%) of the 21 sera from AIC 
reacted with the 74kDa component of bovine heart mi-
tochondria (PDC-E2), and 9 (43%) with the lower mo-
lecular weight E2 subunits of 2-OADC enzymes 
(Figure 1). The antinuclear autoantibodies in AIC re-
acted with centromere, Sp100 and nuclear pore com-
plex proteins as in PBC, but preferentially with the 
nuclear pore complex. Our results have demonstrated 
that AIC and PBC are virtually similar diseases.
Proposed revised categories of "autoimmune 
cholangitis"
 The term "primary biliary cirrhosis" is clearly a mis-
nomer for a disease that has a long precirrhotic stage 
and "cirrhosis" is a relatively late feature of the dis-
ease. 26' "Chronic nonsuppurative destructive cholangitis" 
or "(primary) autoimmune cholangitis" would be a 
more appropriate description, however, "primary biliary 
cirrhosis" is too entrenched a term to be supplanted. 
Goodman et al."' and Dhillon2" have proposed revised 
categories of a group of conditions in which chronic 
nonsuppurative destructive cholangitis is seen 
histologically. They tentatively divided so called 
"autoimmune cholangitis" into four groups (Table 2) .
Future work
 It remains to be determined whether the identifica-
tion of the mitochondrial and nuclear antigens react-
ing with PBC- or AIC-specific autoantibodies will help
Table 2. Revised categories of "autoimmune cholangitis" 
proposed by Dhillon2"
Serology ANA (-) ANA(+) Total 
AMA(+) Type Ia Type lb 
           (classical PBC) (PBC+AIH overlap syndrome) 68%x 
             31%X 37% 
AMA(-) Type Ila Type Iib 
          (seronegative PBC) (autoimmune cholangiopathy) 32% 
             12%" 20%" 
 Total 43%X 57%X
*Data from Goodman et al .") 
ANA: antinuclear antibody, AMA: antimitochondrial antibody, 
PBC: primary biliary cirrhosis, 
AIH: autoimmune hepatitis
Fig. 1 Representative immunoblots from preparation of bo-
vine heart mitochondria probed with PBC serum (lane 1) 
and AIC sera (lanes 2-5). Sera were used at a dilution of 
1:1,000 in lane 2, and 1:5,000 in lanes 1, 3-5. Positive control 
PBC serum with known reactivity with 2-OADC enzymes at 
molecular weights (M.W.) of 74 kDa (PDC-E2), 52 kDa (pro-
tein X), 50 kDa (BCOADC-E2), 46 kDa (OGDC-E2) and 41 
kDa (PDC-E1 alfa) is shown in lane 1. IgG class reactivities 
of AIC sera are shown with a single protein at M.W. of 74 
kDa (PDC-E2) in lane 2, proteins at M.W. of 74 kDa (PDC-
E2) and 50 kDa (BCOADC-E2) in lane 3, a single protein at 
M.W. of 50 kDa (BCOADC-E2) in lane 4, and a non-reactive 
AIC serum is shown in lane 5.
to unravel the pathogenesis of the disease. First, we 
could direct attention to genetic factors, particularly to 
human leukocyte antigens (HLA), which may deter-
mine the autoantibody response to an etiologic agent, 
although HLA only weakly predisposes to PBC vis-a-
vis other autoimmune diseases."' Second, we noted in 
our previous study") that in Japanese patients with 
PBC there was a relatively high frequency of reactiv-
ity with the lower molecular weight components of 2-
OADC such as BCOADC-E2, and this same bias was 
also evident in Japanese patients with AIC.24' It would 
be interesting to elucidate whether this same trend is 
also evident in Caucasian patients with AIC. Third, a 
longitudinal follow-up studies on serological 
reactivities of AMA and ANA in patients with PBC,
AIC and AIH will be useful since it is well known that 
in PBC the AMA titres often fluctuate considerably 
from a negative result to a positive result, and vice 
versa, during the course of the disease.") If so, the di-
agnosis of PBC or AIC might depend on the "phase" of 
the same disease. Such studies are in progress in our 
laboratory. Again, this duo is of interest because, usu-
ally, among sets of autoimmune syndromes, differences 
in serological targetting are relevant to differences in 
clinical manifestations: AIC and PBC are an exception 
to this rule."
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